Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study

References

• Salati M, Cesaretti M, Macchia M, et al. Epidemiological overview of Hodgkin lymphoma across the Mediterranean basin. Mediterr J Hematol Infect Dis. 2014;6(1):e2014048.
   PubMedGoogle Scholar
• Evens AM, Antillón M, Aschebrook-Kilfoy B, et al. Racial disparities in Hodgkin’s lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012;23(8):2128–2137.
   PubMed Web of Science ®Google Scholar
• Shenoy P, Maggioncalda A, Malik N, et al. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol. 2011;2011:1–11.
   Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. NCCN guidelines insights: Hodgkin lymphoma, version 1.2018. J Natl Compr Canc Netw. 2018;16(3):245–254.
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19–iv29.
   PubMed Web of Science ®Google Scholar
• Hoppe R, Advani R, Ai W, et al. Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(6):755–781.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Perales M-A, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158–163.
   PubMed Web of Science ®Google Scholar
• Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017;92(9):879–884.
   PubMed Web of Science ®Google Scholar
• Hewamana S, Kandabadage L, Skandarajah T, et al. Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin lymphoma in Sri Lanka. eClinicalMedicine. 2021;38:100998.
   PubMedGoogle Scholar
• Jaime-Pérez JC, Gamboa-Alonso CM, Padilla-Medina JR, et al. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin’s lymphoma: a decade of experience in a Latin American center. Rev Bras Hematol Hemoter. 2017;39(4):325–330.
   PubMedGoogle Scholar
• Maddi RN, Linga VG, Iyer KK, et al. Clinical profile and outcome of adult Hodgkin lymphoma: experience from a tertiary care institution. Indian J Med Paediatr Oncol. 2015;36(4):255–260.
   PubMedGoogle Scholar
• Price AJ, Ndom P, Atenguena E, et al. Cancer care challenges in developing countries. Cancer. 2012;118(14):3627–3635.
   PubMed Web of Science ®Google Scholar
• Arakelyan J, Movsisyan A, Sargsyan L, et al. Incidence patterns and review of Hodgkin lymphoma in the Republic of Armenia. Ecancermedicalscience. 2021;15:1319.
   PubMed Web of Science ®Google Scholar
• Bair SM, Strelec LE, Feldman TA, et al. Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis. Oncologist. 2019;24(7):955–962.
   PubMed Web of Science ®Google Scholar
• Collins GP, Rueda A, Salles G, et al. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. Leuk Lymphoma. 2018;59(9):2113–2120.
   PubMed Web of Science ®Google Scholar
• Driessen J, Visser O, Zijlstra JM, et al. Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in The Netherlands, 1989–2017. Leukemia. 2021;35(2):494–505.
   PubMed Web of Science ®Google Scholar
• Král Z, Michalka J, Móciková H, et al. Treatment of relapsed/refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia. J Cancer. 2019;10(21):5041–5048.
   PubMed Web of Science ®Google Scholar
• Zagadailov EA, Corman S, Chirikov V, et al. Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk Lymphoma. 2018;59(6):1413–1419.
   PubMed Web of Science ®Google Scholar
• Bhurani D, Nair R, Rajappa S, et al. Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India. Front Oncol. Front Oncol. 2022 Feb 11;11:799948.
   Web of Science ®Google Scholar
• Ramirez P, Ocqueteau M, Rodriguez A, et al. Outcomes in relapsed Hodgkin’s lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile. Rev Bras Hematol Hemoter. 2015;37(3):184–189.
   PubMedGoogle Scholar
• Shamoon RP, Ali MD, Shabila NP. Overview and outcome of Hodgkin’s lymphoma: experience of a single developing country’s oncology centre. PLOS One. 2018;13(4):e0195629.
   PubMed Web of Science ®Google Scholar
• Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, et al. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: real-world data from a single center. World J Clin Oncol. 2021;12(9):800–807.
   PubMed Web of Science ®Google Scholar
• Global atlas of medical devices. Geneva: World Health Organization; 2017 [cited 2022 Mar 15]. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://apps.who.int/iris/handle/10665/255181.
   Google Scholar
• Fernández de Larrea C, Martínez C, Gaya A, et al. Salvage chemotherapy with alternating MINE & ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol. 2010;21(6):1211–1216.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–1072.
   PubMed Web of Science ®Google Scholar
• Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–952.
   PubMed Web of Science ®Google Scholar
• Thomas RK, Re D, Zander T, et al. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol. 2002;13:147–152.
   PubMed Web of Science ®Google Scholar
• Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant. 1997;20(1):21–26.
   PubMed Web of Science ®Google Scholar
• Cuccaro A, Bartolomei F, Cupelli E, et al. Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014053.
   PubMedGoogle Scholar
• Veilleux O, Claveau J-S, Alaoui H, et al. Real-World outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective. Transplantation and cellular therapy. Transplant Cell Ther. 2022;28(3):145–151.
   PubMedGoogle Scholar
• Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073–1079.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–1670.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890–897.
   PubMed Web of Science ®Google Scholar
• Andre MPE, Carde P, Viviani S, et al. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med. 2020;9(18):6565–6575.
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Szabo A, Hamadani M, et al. Contemporary outcomes for advanced-stage classical Hodgkin lymphoma in the U.S.: analysis of surveillance, epidemiology, and end results database. Oncologist. 2019;24(11):1488–1495.
   PubMed Web of Science ®Google Scholar
• Bowhay-Carnes E, Fountzilas C, Janania Martinez M, et al. Chemotherapy relative dose intensity and therapy efficacy in Hodgkin and non-Hodgkin lymphoma: the effect of dose reductions and delays on cure. Blood. 2015;126(23):5092–5092.
   Web of Science ®Google Scholar
• Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin study group HD10 and HD11 trials. J Clin Oncol. 2013;31(12):1522–1529.
   PubMed Web of Science ®Google Scholar
• Brooks EG, Connors JM, Sehn LH, et al. Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2016;57(4):872–879.
   PubMed Web of Science ®Google Scholar